Evidence map›Paper›PMID 41216585›Full record

ArticleAntibody therapeutics2025

Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase.

Claudia Comacchio, Stefanie K Pfister, Domenico Ravazza, Ettore Gilardoni, Tobias Weiss, Michael Weller, Emanuele Puca, Dario Neri, Roberto De Luca

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibody therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claudia ComacchioDepartment of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland.
Stefanie K PfisterDepartment of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland.
Domenico RavazzaDepartment of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland.
Ettore GilardoniDepartment of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland.
Tobias WeissDepartment of Neurology, University Hospital & University of Zurich, Rämistrasse 100, 8091 Zurich (ZH), Switzerland.ORCID https://orcid.org/0000-0002-5533-9429
Michael WellerDepartment of Neurology, University Hospital & University of Zurich, Rämistrasse 100, 8091 Zurich (ZH), Switzerland.ORCID https://orcid.org/0000-0002-1748-174X
Emanuele PucaDepartment of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland.
Dario NeriDepartment of Biology, Philogen Spa, Piazza La Lizza 7, 53100 Siena (SI), Italy.
Roberto De LucaDepartment of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland.ORCID https://orcid.org/0000-0001-7519-8689

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate-specific membrane antigen (PSMA)-targeted therapies have revolutionized the management of patients with prostate cancer. However, not all patients benefit from such agents. Prostatic acid phosphatase (ACP3), a tyrosine phosphatase produced by prostate epithelial cells, has emerged as a promising alternative target for both early and advanced disease. Methods: Here, we report on the generation and characterization of novel, fully human monoclonal antibodies targeting PSMA and ACP3. Antigen-specific clones were isolated from human antibody phage display libraries and characterized Results: Selected clones bound with high specificity to the cognate target and demonstrated excellent tumor-targeting performance in biodistribution studies. Conclusions: The lead candidates, termed H92A5 (anti-PSMA) and EKA4 (anti-ACP3), could serve as promising scaffolds for the development of next-generation tumor-targeted therapeutics for prostate cancer.

Indexed as

prostate cancerprostate specific membrane antigenprostatic acid phosphatasetherapeutic antibodiestumor targeting

Identifiers

PMID41216585
PMCPMC12596256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.